Viracta Therapeutics, Inc.Viracta Therapeutics, Inc.Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪33.64 M‬USD
−1.3194USD
‪−51.06 M‬USD
‪27.49 M‬
Beta (1Y)
2.08

About Viracta Therapeutics, Inc.

CEO
Mark A. Rothera
Headquarters
Cardiff
Employees (FY)
40
Founded
1998
FIGI
BBG000BFG2V7
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of VIRX is 0.8800 USD — it has increased by 2.72% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Viracta Therapeutics, Inc. stocks are traded under the ticker VIRX.
Viracta Therapeutics, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
VIRX stock is 7.14% volatile and has beta coefficient of 2.08. Check out the list of the most volatile stocks — is Viracta Therapeutics, Inc. there?
One year price forecast for Viracta Therapeutics, Inc. has a max estimate of 13.0000 USD and a min estimate of 4.0000 USD.
VIRX earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.31 USD resulting in a −8.20% surprise. The estimated earnings for the next quarter are −0.31 USD per share. See more details about Viracta Therapeutics, Inc. earnings.
Viracta Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪4.50 M‬ USD.
Yes, you can track Viracta Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
VIRX stock has fallen by 14.56% compared to the previous week, the month change is a 15.38% fall, over the last year Viracta Therapeutics, Inc. has showed a 33.83% decrease.
VIRX net income for the last quarter is ‪−13.77 M‬ USD, while the quarter before that showed ‪−12.60 M‬ USD of net income which accounts for −9.25% change. Track more Viracta Therapeutics, Inc. financial stats to get the full picture.
Today Viracta Therapeutics, Inc. has the market capitalization of ‪34.56 M‬, it has increased by 9.62% over the last week.
No, VIRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VIRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viracta Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
VIRX reached its all-time high on Mar 30, 2006 with the price of 9322.1352 USD, and its all-time low was 0.4300 USD and was reached on Dec 19, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 23, 2024, the company has 40.00 employees. See our rating of the largest employees — is Viracta Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viracta Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viracta Therapeutics, Inc. stock shows the sell signal. See more of Viracta Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Viracta Therapeutics, Inc. future price: according to them, VIRX price has a max estimate of 13.00 USD and a min estimate of 4.00 USD. Read a more detailed Viracta Therapeutics, Inc. forecast: see what analysts think of Viracta Therapeutics, Inc. and suggest that you do with its stocks.